Gallant Therapeutics: Funding, Investors & Team (Sep 2026)
Gallant Therapeutics is a biotech company in the field of animal health that specializes in developing stem cell therapies from their stem cell platform. They focus on creating off-the-shelf treatments that can be readily used. Additionally, Gallant is a leading provider of non-invasive stem cell banking services during the spay or neuter process, which allows for new and innovative regenerative medical treatments for animals. Clinical studies have shown the effectiveness of their stem cell therapies in treating various conditions such as osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis. One of their products specifically targets chronic gingivostomatitis in cats, providing a life-saving solution. They also have plans to develop a wide range of treatments for companion animals in the future.
Gallant Therapeutics has raised $15.0M across 1 funding round on record, the most recent a Series A of $15.0M announced in Jan 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Gallant Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2024.
Gallant Therapeutics Funding Rounds
Gallant Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Gallant Therapeutics Funding Compared to Other Biotechnology Startups
Gallant Therapeutics' latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Gallant Therapeutics in Biotechnology and San Diego
Companies Similar to Gallant Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Gallant Therapeutics Funding FAQs
What does Gallant Therapeutics do?
Gallant Therapeutics is a biotech company in the field of animal health that specializes in developing stem cell therapies from their stem cell platform. They focus on creating off-the-shelf treatments that can be readily used. Additionally, Gallant is a leading provider of non-invasive stem cell banking services during the spay or neuter process, which allows for new and innovative regenerative medical treatments for animals. Clinical studies have shown the effectiveness of their stem cell therapies in treating various conditions such as osteoarthritis, atopic dermatitis, chronic kidney disease, and chronic stomatitis. One of their products specifically targets chronic gingivostomatitis in cats, providing a life-saving solution. They also have plans to develop a wide range of treatments for companion animals in the future.
How much funding has Gallant Therapeutics raised?
Gallant Therapeutics has raised $15.0M across 1 round on record. The most recent is a Series A of $15.0M announced in Jan 2024.
When did Gallant Therapeutics last raise funding?
Gallant Therapeutics' most recent funding round on record is a Series A of $15.0M, announced in Jan 2024.
Who founded Gallant Therapeutics?
FundedIQ lists Linda Black (Founder) at Gallant Therapeutics.
Where is Gallant Therapeutics headquartered?
Gallant Therapeutics is based in San Diego, California, United States.
How many employees does Gallant Therapeutics have?
Gallant Therapeutics is in the 11-50 employee band.
How does Gallant Therapeutics' funding compare to other Biotechnology startups?
Gallant Therapeutics' latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Gallant Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Gallant Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.